Matching articles for "finerenone"
Issue 1760 · August 3, 2026
Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy

Sibeprenlimab ( Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with…

Med Lett Drugs Ther. 2026 Aug 3; 68(1760):126-7 doi:10.58347/tml.2026.1760d
Sibeprenlimab ( Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk for disease progression. Sibeprenlimab is the first APRIL blocker to be approved in the US. Atacicept (Trutakna) , a B-lymphocyte stimulator and APRIL blocker, was recently granted accelerated FDA approval for the same indication; it will be reviewed in a future issue.
Issue 1737 · September 15, 2025
A New Heart Failure Indication for Finerenone (Kerendia)

The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):146-8 doi:10.58347/tml.2025.1737b
The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adults with HF with a left ventricular ejection fraction (LVEF) ≥40%. Finerenone was approved in 2021 to reduce the risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes.
Issue 1729 · May 26, 2025
Drugs for Chronic Heart Failure

Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF…

Med Lett Drugs Ther. 2025 May 26; 67(1729):81-8 doi:10.58347/tml.2025.1729a
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Issue 1729 · May 26, 2025 Free
Comparison Chart: Some Drugs for HFrEF

View the Comparison Chart: Some Drugs for HFrEF

Med Lett Drugs Ther. 2025 May 26; 67(1729):e1-15 doi:10.58347/tml.2025.1729b
View the Comparison Chart: Some Drugs for HFrEF
Issue 1668 · January 23, 2023 Free
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal…

Med Lett Drugs Ther. 2023 Jan 23; 65(1668):15-6 doi:10.58347/tml.2023.1668e
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Issue 1631 · August 23, 2021
Finerenone (Kerendia) for Chronic Kidney Disease

Finerenone ( Kerendia – Bayer), an oral nonsteroidal mineralocorticoid receptor antagonist (MRA), has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage renal disease, nonfatal…

Med Lett Drugs Ther. 2021 Aug 23; 63(1631):131-2
Finerenone ( Kerendia – Bayer), an oral nonsteroidal mineralocorticoid receptor antagonist (MRA), has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage renal disease, nonfatal MI, hospitalization for heart failure (HF), and cardiovascular death in adults with chronic kidney disease (CKD) associated with type 2 diabetes. It is the first nonsteroidal MRA to be approved in the US.